Funding for this research was provided by:
Text and Data Mining valid from 2018-09-12
Received: 2 October 2017
Accepted: 13 August 2018
First Online: 12 September 2018
Change Date: 8 April 2019
Change Type: Correction
Change Details: Following publication of the original article , the authors notified us that a comment in the Peripheral and neural biomarkers and genotype section was incorrectly phrased during editing. “4 weeks of treatment (four active ABCR sessions twice a week or control group sessions twice a week)” should have actually been described as “4 weeks of treatment (4 active, twice a week, ABCR sessions or 2 weekly control group sessions)”.
Ethics approval and consent to participate
: The study has been approved by the Ethics Committee in the Capital Region of Denmark (protocol H-16043480) and the Danish Data Protection Agency (2012-58-0004). It was retrospectively registered at ExternalRef removed (NCT03295305) on 26 September 2017 (ExternalRef removed). Written informed consent will be obtained from all participants. Any important changes in the protocol will be reported to the Ethics Committee in the Capital Region of Denmark and the Danish Data Protection Agency.
: Not applicable.
: KWM has received consultant fees from H. Lundbeck and Allergan. MV has received consultancy fees from H. Lundbeck and Astra Zeneca within the last 3 years. LVK has been a consultant for H. Lundbeck, AstraZeneca, and Sunovion within the last 3 years. EMC has received honoraria from H. Lundbeck within the last 3 years. CRB has received honoraria from Boehringer Ingelheim, Lundbeck, Otsuka, and Abbie. CVO has no competing interests. GMK has not received any honoraria from pharmaceutical companies within the last 3 years. The computer software used in the ABCR group is provided free of charge by HappyNeuron Pro (ExternalRef removed).
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.